SCHEMBL2393320

SCHEMBL2393320

CCOC(=O)CNc1ccc(Cl)cc1Oc1ccc(S(=O)(=O)CC)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 8/20 0.47
GAA P10253 1/20 0.41
LMNA P02545 1/20 0.40
ALDH1A1 P00352 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38
CCR2 P41597 2/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394816 0.88 PTGDR2 (0.55) PTGDR2ALDH1A1CCR2POLBKDM4E
SCHEMBL2395020 0.84 GAA (0.43) GAALMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL2396776 0.82 LMNA (0.48) GAALMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL27849058 0.79 ALDH1A1 (0.47) PTGDR2GAALMNAALDH1A1L3MBTL1
SCHEMBL2392884 0.78 PTGDR2 (0.55) PTGDR2CCR2PTGS1PTGS2
SCHEMBL2394830 0.78 PTGDR2 (0.46) PTGDR2ALDH1A1KMT2ACCR2POLB
SCHEMBL24460021 0.77 ALDH1A1 (0.56) GAALMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL1333658 0.76 PTGDR2 (0.52) PTGDR2LMNAALDH1A1HPGDPOLB
SCHEMBL1332548 0.76 PTGDR2 (0.71) PTGDR2
SCHEMBL2398422 0.76 PTGDR2 (0.59) PTGDR2KMT2ACCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
US-8022248-B2 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid ASTRAZENECA AB (SE) 2011-09-20 US disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 PTGDR2 176/4885GAA 359/4885LMNA 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.